Noriko Kishida

Noriko Kishida

Auto-generated profile, based on publicly available information

Noriko Kishida

Laboratory of Influenza Virus Surveillance Research Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases Tokyo Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Journal of General Virology
Verified
Journal Article
Open access
TYTingting Yang
Tingting Yang
MKMichiyo Kataoka
Michiyo Kataoka
YAYasushi Ami
Yasushi Ami
YSYuriko Suzaki
Yuriko Suzaki
NKNoriko Kishida
Noriko Kishida
TLTiancheng Li
Tiancheng Li
Ferret hepatitis E virus (HEV), a novel hepatitis E-like virus, has been identified in ferrets in The Netherlands. Due to the lack of a cell-culture system for ferret HEV, the antigenicity, pathogenicity and epidemiology of this virus have remained unclear. In the present study, we used a recombinant baculovirus expression system to express the 112-N-terminus and 47-C-terminus-amino-acid-truncated ferret HEV ORF2 protein in insect Tn5 cells, and found that a large amount of a 53 kDa protein (F-p53) was expressed and efficiently released into the supernatant. Electron microscopic analysis revealed that F-p53 was self-assembled into virus-like particles (ferret HEV-LPs). These ferret HEV-LPs were estimated to be 24 nm in diameter, which is similar to the size of G1, G3, G4 and rat HEV-LPs derived from both the N-terminus- and C-terminus-truncated constructs. Antigenic analysis demonstrated that ferret HEV-LPs were cross-reactive with G1, G3, G4 and rat HEVs, and rat HEV and ferret HEV showed a stronger cross-reactivity to each other than either did to human HEV genotypes. However, the antibody against ferret HEV-LPs does not neutralize G3 HEV, suggesting that the serotypes of these two HEVs are different. An ELISA for detection of anti-ferret HEV IgG and IgM antibodies was established using ferret HEV-LPs as antigen, and this assay system will be useful for monitoring ferret HEV infection in ferrets as well as other animals. In addition, analysis of ferret HEV RNA detected in ferret sera collected from a breeding colony in the USA revealed the genetic diversity of ferret HEV.

1 January 2020 in International Journal of Business Innovation and Research
Verified
Journal Article
Closed access
KTKazuhiko Tsuda
Kazuhiko Tsuda
YJYuexian Jin
Yuexian Jin
TUTakahiko Umeyama
Takahiko Umeyama
TKTakumi Kato
Takumi Kato
NKNoriko Kishida
Noriko Kishida

8 November 2024 in Microbiology and Immunology
Verified
Journal Article
Open access
NKNoriko Kishida
Noriko Kishida
MIMasaki Imai
Masaki Imai
AAAkira Ainai
Akira Ainai
HAHideki Asanuma
Hideki Asanuma
RSReiko Saito
Reiko Saito
SWShinji Watanabe
Shinji Watanabe
It has been reported that the high‐growth reassortant (HGR) A(H3N2) influenza viruses used for split influenza vaccine (SV) production have some amino acid substitutions in hemagglutinin due to egg adaptation during virus propagation, causing antigenic differences between HGR and epidemic viruses. To clarify whether inactivated whole‐virus vaccine (WV) derived from the A(H3N2) HGR virus possessing egg adaptation could induce cross‐protective immune responses against epidemic A(H3N2) viruses, the efficacy of WV was compared with that of SV in a ferret model. When the ferrets immunized with WV or SV derived from HGR A/Victoria/361/2011 (IVR‐165) virus were challenged with the homologous virus A/Victoria/361/2011 (IVR‐165) or its original cell‐propagated A/Victoria/361/2011 virus, respectively, WV successfully shortened the duration of virus shedding of both challenge viruses, whereas SV shortened only that of the homologous virus, A/Victoria/361/2011 (IVR‐165). When WV‐immunized ferrets were challenged with A/Fukushima/69/2015 virus, which is an epidemic virus antigenically different from the A/Victoria/361/2011 virus, WV could shorten the duration of shedding of this virus. In addition, we found that early induction of nasal IgG and IgA antibodies by vaccines helped shorten the virus‐shedding period, although this was dependent on the degree of difference in antigenicity of the challenge virus. These results indicate that vaccination with WV, not with SV, would be a solution to avoid decreased vaccine effectiveness due to the antigenic change of HGR virus by egg adaptation during virus propagation.